Objectives: The aims of this study were to determine if activating KRas mutation alters estrogen signaling in endometrial cancer (EC) and to explore the potential therapeutic impact of these alterations. Methods: The Cancer Genome Atlas was queried for changes in estrogen-regulated genes in EC based on KRas mutation status. In vitro studies were conducted to evaluate estrogen receptor > (ER>) phosphorylation changes and related kinase changes in KRas mutant EC cells. The resulting effect on response to MEK inhibition, using trametinib, was evaluated. Immunohistochemistry was performed on KRas mutant and wild-type EC tumors to test estrogen signaling differences. Results: KRas mutant tumors in The Cancer Genome Atlas showed decreased progesterone receptor expression (P = 0.047). Protein analysis in KRas mutant EC cells also showed decreased expression of ER> (P G 0.001) and progesterone receptor (P = 0.001). Although total ER> is decreased in KRas mutant cells, phospho-ER> S118 was increased compared with wild type. Treatment with trametinib in KRas mutant cells increased phospho-ER> S167 and increased expression of estrogen-regulated genes. While MEK inhibition blocked estradiol-stimulated phosphorylation of ERK1/2 and p90RSK in wildtype cells, phospho-ERK1/2 and phospho-p90RSK were substantially increased in KRas mutants. KRas mutant EC tumor specimens showed similar changes, with increased phospho-ER> S118 and phospho-ER> S167 compared with wild-type EC tumors. Conclusions: MEK inhibition in KRas mutant cells results in activation of ER signaling and prevents the abrogation of signaling through ERK1/2 and p90RSK that is achieved in KRas wild-type EC cells. Combination therapy with MEK inhibition plus antiestrogen therapy may be necessary to improve response rates in patients with KRas mutant EC.
E ndometrial cancer (EC) remains the most common gynecologic cancer in the United States, with an estimated 60,050 new cases and 10,470 deaths in 2016. 1 The majority of women who present with EC receive a diagnosis of earlystage disease and have a favorable overall survival of 80% to 90%. 2 Unfortunately, women who experience recurrence have poor response to current therapies, with an overall survival of 12 months. 3 Unopposed estrogen is a well-established risk factor for the development of EC 4 and is known to drive proliferative signals. The majority of endometrioid ECs express the estrogen receptor (ER), emphasizing the role for estrogen in the development and progression of EC. 5Y7 While patients with low-grade, hormone receptorYpositive EC generally have a favorable prognosis, the majority of recurrences occur in this subset because 80% of ECs fit into this subtype. 2 First-line treatment for recurrent EC includes antiestrogen hormonal therapies; yet, low response rates of only 10% to 30% have been observed in recurrent EC. 8Y11 Recent studies from The Cancer Genome Atlas (TCGA) have shown that uterine cancer is heterogeneous at the molecular level and can be further subdivided into several clusters, which include aberrations beyond the ER pathway and in pathways that have cross talk with ER signaling. 12, 13 Therapeutic resistance is not well understood in EC. However, previous studies in breast cancer have found that activation of the Ras/MAPK pathway is associated with resistance to antiestrogen treatment. 14Y16 Oncogenic alterations in Ras/MAPK pathway occur in the form of activating KRas mutations in 10% to 30% of endometrioid EC. Unfortunately, similar to responses to antihormone therapy alone, singleagent activity of MEK inhibitors has been very limited, and an improved understanding of interactions through these signaling pathways will be critical to overcoming resistance. 17 Our previous EC studies have characterized a panel of estrogen-regulated genes as a readout of ER activity. 18 Estrogen receptor signaling action occurs through not only the classic ligand-dependent genomic mechanisms via direct or tethered binding to estrogen response elements but also nongenomic (nontranscriptional) rapid signaling. 19 The exact mechanisms of nongenomic signaling are less clear but result in activation of various kinases to induce phosphorylation of ER> and lead to rapid signaling activation. 20 At least 5 serine residues of the N-terminal domain of ER> has been identified as phosphorylation sites, of which S118 and S167 are the best characterized. Phosphorylation of both of these sites occurs through several different mechanisms. Ligand-dependent phosphorylation, as a result of estrogen binding, occurs at S118. 21 Activation of ER> can also be accomplished through ligandindependent phosphorylation at both S118 and S167 by several member kinases of receptor tyrosine kinase pathways, such as the PI3K/AKT and Ras/MAPK pathways. ERK1/2 phosphorylates S118 and is independent from the phosphorylation that occurs as a result of estrogen binding. 22Y24 In addition, AKT, p70S6K, and p90RSK have been found to phosphorylate and activate ER> at S167.
25Y30
Based on previous studies of hormone resistance in breast cancer, we hypothesized that ECs with activating KRas mutations would have aberrant signaling through ER>. We further hypothesized that targeted treatment against Ras/ MAPK pathway would result in differential changes in ER signaling in KRas mutant EC cells compared with wild type. Signaling through ER based on KRas mutation status could have important implications in the treatment of EC and inform the design of improved combination therapeutic strategies.
METHODS

The Cancer Genome Atlas
In collaboration with our institution's Bioinformatics and Biostatistics Resource Group, TCGA was queried to identify endometrioid adenocarcinomas of the uterus. Cases lacking PI3K pathway aberrations were excluded to focus on the effect of KRas mutation status. RNA sequencing (RNAseq) version 2 data were downloaded from http://cancergenome. broadinstitute.org, log2 transformed, and feature-by-feature 2-sample t tests were performed to compare profiles between samples with and without KRas mutations. Beta-uniform (BUM) models were used to fit the P value distributions to adjust for multiple comparisons. 
Cell Culture and Reagents
Reverse-Phase Protein Array
Reverse-phase protein array (RPPA) was performed by the Functional Proteomics Core. Ishikawa cells expressing wildtype or mutant KRas (G12V) were serum starved overnight for 12 hours in phenol-free Dulbecco modified Eagle medium with L-glutamine containing vehicle (dimethyl sulfoxide) or 10 nM trametinib. Cells were then stimulated with 0.01 KM estradiol, and cell lysates were harvested at 30 minutes.
Serially diluted lysates were arrayed on nitrocellulosecoated slides (Grace Biolab, Bend, OR) and then probed, analyzed, and quantitated as previously described. 31 Each dilution curve was fitted with a logistic model (''Supercurve Fitting'' developed by the Department of Bioinformatics and Computational Biology at M. D. Anderson, http://bioinformatics. mdanderson.org/OOMPA). The protein concentrations of each set of slides were then normalized by median polish, which was corrected across samples by the linear expression values using the median expression levels of all antibody experiments to calculate a loading correction factor for each sample.
Data were analyzed using Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA) to evaluate changes in molecular functions and canonical signaling pathways.
Western Blot
Ishikawa cells stably transfected with wild-type KRas and mutant KRas (G12V) were treated with vehicle (dimethyl sulfoxide) or 10 nM trametinib and stimulated with estradiol, as described previously. Primary antibody (1:1000Y1:2000 dilution) incubations were performed overnight at 4-C. Phospho-ER> (Ser167) (D1A3) rabbit mAb, phospho-ER> (Ser118) (16 J4) mouse mAb, ER> (D8H8) rabbit mAb, phospho-AKT (Ser473) (D9E) XP rabbit mAb, AKT rabbit mAb, phospho-p70 S6 kinase (Thr389) rabbit mAb, phospho-p44/42 MAPK (ERK1/2) rabbit mAb, p44/42 MAPK (ERK1/2) rabbit mAb, and phospho-p90RSK (Ser380) rabbit mAb were purchased from Cell Signaling Technology (Danvers, MA). Blots were reprobed using antiYA-actin mouse mAb (Sigma). Relative densities were calculated using Image J software (National Institutes of Health, Bethesda, MD). All experiments were performed in triplicate.
Gene Expression
Quantitative real-time polymerase chain reaction was performed for estrogen-regulated genes 18 through the Quantitative Genomics and Microarray Core at the University of Texas Medical School at Houston. Ishikawa cells stably transfected with wild-type KRas or mutant KRas (G12V) were treated with vehicle or trametinib, followed by estradiol, as described previously, and harvested 16 hours later. Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) with DNAase treatment.
Patient Specimens and Immunohistochemistry
Endometrial tumors were obtained from archived specimens in the Gynecologic Oncology Tumor Bank. KRas status was determined from clinical mutation analysis (as reported in the medical record) or via polymerase chain reactionYbased Sanger sequencing at the Sequencing and Microarray Core. 32 All specimens were endometrioid EC, low grade, and obtained from primary hysterectomy. Primary antibodies against phospho-ER> (S167), phospho-ER> (S118), progesterone receptor (PR; Cell Signaling Technology), and total ER (Dako, Carpinteria, CA) were used to stain KRas wildtype (n = 10) and KRas G12V mutant (n = 5) specimens. Negative controls were run in parallel, with primary antibody replaced with antibody dilution buffer. Staining was imaged with Vectra 3 automated quantitative pathology system and analyzed with inForm software (PerkinElmer, Waltham, MA) in collaboration with the Flow Cytometry and Cellular Imaging Facility. Expression was quantified using H-scores, determined by percentage and staining strength (negative, 1+, 2+, 3+) of positive nuclear staining.
Statistical Analysis
Data were analyzed with independent t test for pairwise comparisons using GraphPad Prism 7 (GraphPad Software, La Jolla, CA). For multiple comparisons, analysis of variance was used with the Tukey test.
RESULTS
Endometrial Tumors With KRas Mutations Express Decreased Progesterone Receptor
Two hundred forty-one patients with EC had both mutation and RNAseq data available in TCGA. Only endometrioid tumors were included in our analysis, resulting in 194 cases. Of these, 9 tumors lacked PI3K pathway alterations and were excluded to focus on the effects of KRas mutation status. Of 185 endometrioid EC cases with PI3K pathway aberrations, 49 tumors (26.5%) had a confirmed KRas mutation (specific mutations listed in Table 1 (Fig. 1) . IGF1, another gene modified by ER signaling, was also downregulated in KRas mutant endometrioid EC.
KRas Mutant EC Cells Have Altered Response to Estradiol Stimulation
In vitro studies were then used to evaluate rapid molecular changes due to activating KRas mutation following estradiol stimulation in EC cells. Changes at the protein level were evaluated using RPPA and then Ingenuity Pathway Analysis. At 30 minutes following estradiol stimulation, KRas mutant Ishikawa cells had decreased expression of ER> and decreased expression of PR compared with Ishikawa cells expressing wild-type KRas (Fig. 2) . Top canonical pathways significantly activated were ErbB2YErbB3 signaling (P = 1.30e-21), ErbB signaling (P = 4.33e-19), and EGF signaling (P = 1.24e-17). Proteins included in these pathways overlapped significantly and included NRG1, EGFR, HER2, HER3, SHC, c-RAF, p27-Kip1, MEK1/2, p38MAPK, JNK, PI3K, mTOR, and STAT3/5. ERK/MAPK signaling was also identified as significantly activated. In addition, upstream regulators analysis indicated the top 2 regulators to be ER> and PTEN. This global pathway analysis confirms our observations in TCGA analysis, which is that KRas mutation status not only drives activation of Ras/MAPK signaling but also indicates alterations in growth factor signaling and interactions with estrogen signaling.
KRas Mutant Ishikawa Cells Exhibit Altered Rapid Estrogen Signaling and Altered Response to MEK Inhibition
Further analysis of ER was needed to capture alterations in activity through phosphorylation states, as well as signaling changes in intersecting pathways. To evaluate activation of estrogen signaling, phosphorylated-ER quantitation was normalized to total ER>, which was decreased in the KRas mutant cells (Fig. 3) . Differences in phosphorylation of S118 and S167 in response to estradiol stimulation compared with no stimulation were observed based on KRas mutation status (vehicle vs 30-minute time point). As shown in Figure 3A , phosphorylation at S118 was increased by estradiol stimulation at 30 minutes compared with vehicle in both wild type and KRasG12V. However, the magnitude of induction is reduced in KRasG12V. Phosphorylation at S167 is increased by estradiol stimulation compared with vehicle only in wild-type cells.
We then evaluated phosphorylation of S167 and S118 at the 30-minute time point to evaluate differences in phosphorylated states between KRas wild-type and mutant cells. KRas wild-type cells had increased phosphorylation at S167 compared with KRas mutant cells. However, cells with mutant KRas had increased phosphorylation at S118 after estradiol stimulation compared with cells with wild-type KRas (Fig. 3) .
To evaluate the direct influence of the Ras/MAPK pathway in differential estrogen signaling, Ishikawa cells were treated with 10 nM trametinib, an MEK inhibitor, prior to estradiol stimulation, and Western blots were performed to evaluate signaling through ER> (Fig. 3) . MEK inhibition did not create a large change in total ER> for wild-type or KRas mutant cells. Following treatment with trametinib, cells with wild-type KRas maintained a similar response to estradiol stimulation, with little change to phosphorylation at S118, but perhaps a slightly modified time course for S167, with decreased phosphorylation at 30 minutes and increased phosphorylation of S167 at the 1-hour time point. MEK inhibition in mutant KRas cells resulted in minimal changes to levels of phosphorylation at S118 and an increase in phosphorylation at S167 after estradiol stimulation, indicating activation of rapid estrogen signaling. Interestingly, phosphorylation of ER> S167 without estrogen stimulation (vehicle) is increased in the presence of MEK inhibitor, suggesting activation of ligand-independent estrogen signaling. 
KRas Mutation Decreases Estradiol-Stimulated Signaling Through Ras/MAPK Pathway and Causes Differential Response to MEK Inhibition
AKT, p70S6K, ERK1/2, and p90RSK are able to phosphorylate ER> to activate rapid nongenomic signaling. For this reason, phosphorylation at these points in the PI3K/AKT and Ras/MAPK pathways was evaluated.
No differences were observed for AKT phosphorylation or p70S6K phosphorylation between wild-type and mutant KRas cells. Treatment with trametinib resulted in minimal change in phosphorylation of either AKT or p70S6K in either cell type (Fig. 4) . Cells with mutant KRas demonstrated a decrease in phosphorylation of ERK1/2 and p90RSK after estradiol stimulation compared with wild type. While MEK inhibition blocked estradiol-stimulated phosphorylation of ERK1/2 in wild-type KRas cells, phospho-ERK1/2 was substantially increased in mutant KRas cells. Similar to the pattern of phospho-ERK1/2, MEK inhibition decreased phosphop90RSK in wild-type cells but led to increased phosphop90RSK in KRas mutant cells (Fig. 4) .
MEK Inhibition in Mutant KRas Cells Results in Up-regulation of Estrogen-Regulated Genes
The functional effect of KRas mutation and MEK inhibition was evaluated at the gene expression level. Expression of sFRP1 was decreased j1.85-fold (P = 0.002), and RALDH2 was decreased j3.87-fold (P = 0.006), in KRas mutant cells compared with wild type. These genes contribute to the inhibition of estrogen-driven proliferation. Relative expression of these genes was not significantly changed when cells with wildtype KRas were treated with trametinib. However, MEK inhibition in KRas mutant cells increased relative expression of 4 estrogen-regulated genes, EIG121 (P = 0.001), sFRP1 (P G 0.0001), PR (P = 0.0003), and HOXA10 (P = 0.002) (Fig. 5) .
Immunohistochemistry Shows Altered ER Signaling in KRas Mutant Tumors
To test these observations in human endometrial tumors, markers of ER signaling were evaluated in untreated endometrioid ECs with wild-type (n = 10) or mutant KRas (n = 5). Staining showed that total ER was not significantly different, but phospho-ER S167 and phospho-ER S118 were . Differences in phosphorylation of S118 and S167 in response to estradiol stimulation were observed based on KRas mutation status (vehicle vs 30-minute time point). A. Phosphorylation at S118 was increased by estradiol stimulation at 30 minutes in both wild type and KRasG12V. However, the magnitude of induction is reduced in KRasG12V. Baseline phosphorylation at S167 is increased by estradiol stimulation only in wild-type cells. We then evaluated phosphorylation of S167 and S118 at the 30-minute time point to evaluate differences in phosphorylated states between KRas wild-type and mutant cells. KRas wild-type cells had increased phosphorylation at S167 compared with KRas mutant cells. Cells with mutant KRas had increased phosphorylation at S118 after estradiol stimulation compared with cells with wild-type KRas. Following treatment with an MEK inhibitor, KRas mutant cells have increased phosphorylation at S167. The triangle on the left indicates the band of interest for phosphorylation of S167. B, Graphical depiction of immunoblot results at the 30-minute time point expressed as normalized relative density. Phospho-ERs are normalized to total ER>; ER> is normalized to A-actin control. V indicates vehicle. Cells were stimulated with 0.01 KM estradiol, and cell lysates were harvested at 10 minutes, 30 minutes, 1 hour, and 4 hours. All experiments were performed in triplicate.
significantly increased in KRas mutant tumors compared with wild-type (P G 0.001 and P = 0.033, respectively). Progesterone receptor was significantly reduced in KRas mutant tumors (P = 0.044, Fig. 6 ).
DISCUSSION
We investigated ER> signaling alterations associated with KRas mutations across large-scale genomic data from TCGA, using in vitro studies and using human tumor specimens to evaluate the role of Ras/MAPK signaling in relation to estrogen signaling in EC. Understanding these intersecting pathways has important implications for rational therapeutic strategies. In evaluating rapid estrogen signaling, we demonstrated that KRas mutant EC cells have decreased expression of estradiol-stimulated total ER> compared with cells with wild-type KRas. However, levels of total ER> do not tell the full story of ER signaling in these cells; KRas mutant cells show activation of estrogen signaling through phosphorylation of ER> at S118 in response to estradiol stimulation. Furthermore, MEK inhibition in KRas mutant cells results in additional activation of ER> signaling through increased phosphorylation at S167. Consistent with this 6 . Immunohistochemical staining was conducted on endometrioid endometrial tumor specimens to compare ER and PR expressions in KRas wild-type and KRas mutant tumors. Progesterone receptor expression was lower in KRas mutants (P = 0.044). KRas mutants showed increased expression of phospho-ER> S118 (P = 0.033) and phospho-ER> S167 (P G 0.001).
status in predicting potential clinical response to MEK inhibitors and rational combination therapies. Evaluation of ER signaling in KRas wild-type and mutant endometrial tumor specimens confirmed baseline activation of ER signaling through phosphorylation at S118 and S167 with a paradoxical decrease in PR.
Although further questions remain, this study provides 2 particularly potent points of relevance to clinical treatment of EC and future study design. First, KRas mutant ECs have increased activation of estrogen signaling that is mediated through Ras/MAPK pathway and provides a route to circumvent MEK inhibition with trametinib to ultimately upregulate MAPK signaling. This suggests that combination treatment with antiestrogen therapy will be required for efficacy in patients with KRas mutant tumors. Second, both in vitro studies and immunohistochemistry of human tumor samples highlight that the traditional evaluation of total ER> and PR is not a definitive indicator of ER signaling activity. While total levels may be reduced, phosphorylation and subsequent activation are increased. Evaluation of phosphospecific ER> markers can provide critical information about baseline tumor biology but, even more importantly, help identify appropriate therapeutic combinations and better understand response to molecularly targeted agents.
This study focuses on changes in ER signaling at short time points (from 10 minutes to 4 hours). This approach enabled evaluation of rapid activation of the Ras/MAPK and PI3K/AKT pathways and corresponding alterations in phosphorylation of ER>. Yet, additional intersecting signaling pathways are likely, and there remains the possibility that genomic ER signaling could also be altered even at these short time points. However, this study provides a critical snapshot of rapid changes in ER signaling related to activating KRas mutations in EC and identifies related differential response to MEK inhibition. This information is of interest in predicting sensitivity to treatment with various therapeutic combinations.
One limitation of our study is that we used Ishikawa EC cells to transfect wild-type and mutant KRas for the in vitro model, as Ishikawa cells exhibit loss of PTEN expression at baseline. Indeed, activation of the PI3K/AKT pathway has been shown to be a predictive marker for nonresponse to MEK inhibition in KRas mutant cancers. 33 However, this is an important characteristic of our in vitro studies, as activation of the PI3K/AKT and Ras/MAPK pathways co-occurs in a proportion of endometrial tumors. 34Y36 In addition, as activation of PI3K/AKT has been implicated as a mechanism of acquired resistance, this suggests that our findings are relevant both for advanced cancers with these aberrations and for tumors that have acquired resistance following treatment with MEK inhibitors. In the context of these in vitro studies, both the wild-type and mutant KRas cells exhibited loss of PTEN expression, so this molecular aberration was controlled for in our in vitro model.
While KRas has proven difficult to target, MEK inhibitors are currently being investigated in phases 1 and 2 trials in various cancer types. MEK inhibitors bind adjacent to the ATP binding site on MEK, leading to noncompetitive interference with MEK function. As a result, MEK inhibitors are highly specific. This specificity is heightened as ERK is the only known downstream effector of MEK. 37 In preclinical studies, MEK inhibitors have been found to be cytostatic but not cytotoxic, supporting the notion that additional agents are needed in addition to MEK inhibitors to affect tumor regression. 38 In addition, while BRAF mutant tumors are sensitive to MEK inhibition, tumors with activating KRas mutations have shown more variable responses. 33, 39 A singlearm phase 2 Gynecologic Oncology Group trial of AZD6244, a MEK1/2 inhibitor, was performed in patients with advanced or recurrent EC. The objective response rate was only 6%; however, 13 patients had stable disease. 40 In addition, multiple hormonal therapies have been evaluated in the treatment of recurrent EC, with response rates ranging from 10% to 30%.
8Y11 Single-agent letrozole, an aromatase inhibitor, showed a response rate of only 9.4% in this patient population. The addition of antihormonal therapy to MEK inhibition may provide added benefit for patients with recurrent EC compared with either therapy alone. These findings provide preclinical support for the combination of endocrine therapy and MEK inhibition in the treatment of KRas mutant endometrial tumors.
